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AGEING, CARDIOVASCULAR DISEASES AND CANDIDATA GENE 
POLYMORPHISMS 
SUMMARY 
Ageing is a multifactorial phenomenon and affected from genetic and environmental   
factors. It is the process of systems’ deterioration with time and involves many 
changes at biochemical and morphological levels. Association of genes with 
successful ageing is started to become clear in recent years. In an initial study about 
successful ageing, Payami and his friends have shown that the risk of becoming 
senile in relatives of successfully aged people is lower than relatives of Alzheimer 
patients and people in normal population. A more recent study which has been done 
on centerineans has shown that the absence of M694V mutation on MEFV gene, 
which is an inflammatory gene, could be related to living longer and healthly. It has 
been shown that  centenarian offspring has less cardiovascular disease (CVD) and 
ischaemic heart disease when compared with age-matched controls. It also has been 
demonstrated that cancer is delayed in families of centenarians. 
Cardiovascular disease (CVD) is the most common reason of illness and death in the 
world, both in developed and developing countries. It is observed that protection 
from CVD enables to live longer and healthy. From pervious studies, it is also known 
that there is a significant relationship with inflammation and CVD. Thus, a person 
without choronic inflamatory diseases have lower risk for CVD. 
In our project, we have analysed the association of APOE, LDLR, SIRT3 and 
APOJ/Clusterin genes’ polymorphisms in an elderly population (N=170) without a 
major chronic or acute disorder including inflammatory and heart diseases. These 
polymorphisms have been previously associated either with healthy aging or heart 
diseases. Our hypothesis was to test the frequency of the protective alleles between 
the elderly population and the historic controls from general population. We also did 
some serum analyses in this sample and RF (rheumatoid Factor), hsCRP (high 
sensitivity-C reactive Protein) and clusterin levels were analysed and the latter was 
also compared with young controls (N=38) without a major disorder. After finding 
variations on the clusterin serum levels we have searched for polymorphism and/or 
mutations on APOJ gene using Denaturing Gradient Gel Electrophoresis ( DGGE ) 
method. Our results indicate that there are not associaton between SIRT3 and LDLR 
genes polymorphisms and longevity. We have seen a positive correlation between 
protective ε2 allele of APOE gene with longevity (P<0.0001). We have also detected 
a positive correlation between serum clusterin levels and longevity in males 
(P=0.0005). We have seen an association between serum clusterin levels and hsCRP 
levels (P=0.001), and we have shown a positive correlation between LDLR C1959T 
polymorphism with hypertension (P=0.042).   
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YAŞLANMA, KALP DAMAR HASTALIKLARI VE ADAY GEN 
POLİMORFİZMLERİ 
ÖZET 
Yaşlanma, multifaktoriyel bir olaydır ve genetik ve çevresel faktörlerden tarzından 
etkilenir. Zamanla sistemlerin bozulması sürecidir ve biyokimyasal ve morfolojik 
düzeyde birçok değişikliği içerir. Son yıllarda, bir takım genlerin sağlıklı yaşlanma 
ile ilişkisi açıkca belirlenmeye başlanmıştır. Payami ve arkadaşları sağlıklı ve uzun 
yaşamış yaşlıların akrabalarındaki bunama riskinin serbest toplumdaki ve Alzheimer 
hastalarının akrabalarındaki riskten daha az olduğunu göstermiştir. Yüzyıllık 
yaşlılarda yapılan daha yeni bir çalışma, iltihapla ilişkilendirilen MEFV inflamasyon 
genindeki M694V mutasyonu olmamasının daha uzun ve sağlıklı yaşamla ile ilgili 
olabileceğini  göstermiştir. Sağlıklı yaşlıların çocuklarının daha az kalp damar 
hastalığı (KDH) ve iskemik kalp hastalığı riski taşıdıkları yaşıtlarıyla karşılaştırılarak 
gösterilmiştir. Ayrıca, sağlıklı yaşlıların ailelerinde kanserin ortaya çıkışının da 
geciktiği gösterilmiştir. 
Kalp damar hastalığı (KDH) bütün dünyadaki gerek gelişmiş gerekse gelişen 
devletlerde en yaygın hastalık ve ölüm nedenidir. KDH’ dan korunmuş olmanın 
sağlıklı ve uzun yaşamaya imkan tanıdığı gözlemlenmiştir. Önceki çalışmalardan 
KDH ile inflamasyon arasında önemli bir ilişki olduğu bilinmektedir. Bu yüzden, 
kronik inflamatuvar hastalıkları olmayan bir insan KDH için daha az risk taşıyor 
olabilirler. 
Biz bu projemizde; APOE, LDLR, SIRT3 ve APOJ/Clusterin genlerindeki 
polimorfizmlerin sağlıklı yaşlanma ile ilişkisini kalp hastalığı da dahil olmak üzere 
herhangi bir kronik inflamatuvar hastalığı olmayan yaşlı bir grupta araştırdık 
(N=170). Bu genlerin özelliği önceki çalışmalarda kalp damar hastalıklarıyla ve 
sağlıklı yaşlanmayla ilişkilendirilmiş olmalarıdır. Bizim hipotezimiz, bu genlerdeki 
koruyucu allellerin sıklığının genel populasyonla karşılaştırılmasıdır. Ayrıca serum 
RF (romatoid faktör), hsCRP (yüksek duyarlıklı c-reaktif protein) ve clusterin 
düzeylerini belirledik ve yaşlı grubumuzun serum Clusterin seviyelerini herhangi bir 
önemli hastalığı bulunmayan genç bir kontrol grubuyla (N=38) karşılaştırdık. Serum 
clusterin düzeyleri arasında bir farklılık bulduktan sonra, APOJ geni üzerindeki 
mutasyon ve/veya polimorfizmleri Denaturing Gradient jel elektroforezi yöntemi ile 
araştırdık. Sonuçlarımız LDLR ve SIRT3 genlerindeki polimorfizmlerin sağlıklı 
yaşlanma ile ilişkili olmadığını gösterdi. APOE genindeki koruyucu e2 alleli ile 
sağlıklı yaşlanma arasında pozitif bir ilişki gördük (P<0.0001). Aynı zamanda, 
erkeklerde serum clusterin düzeyleri ile sağlıklı yaşlanma arasında pozitif bir ilişki 
belirledik (P=0.0005). Serum clusterin düzeyleri ile serum hsCRP düzeyleri arasında 
bir ilişki gördük (P=0.001) ve LDLR C1959T polimorfizmi ile hipertansiyon 
arasında pozitif bir ilşki gösterdik (P=0.042).  
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1. INTRODUCTION 
1.1. Ageing and Longevity 
Ageing is a multifactorial phenomenon that is influenced both by genetic and 
environmental factors. It is the process of systems’ deterioration with time and 
involves many changes at biochemical and morphological levels. Helfand and 
Rogina identify ageing as an inevitable consequence of being a multicellular 
organism, associated with a random, passive decline in function, leading to a global 
loss of homeostasis over time and an increase in mortality [1, 2]. 
Many theories have been suggested to understand presence of senescence that 
explain when it occurs, and what are the biological processes responsible for it. 
These theories can be divided into two main classes: Biochemical and evolutionary. 
The biochemical theory invokes damages on DNA, cells, tissues, and organs and 
connects senescence with imperfections in the biochemical processes. A kind of this 
biochemical imperfection is the presence of free radicals that can cause death of the 
cells or may even lead to cancer. On the other hand, the evolutionary theory explains 
senescence as a competitive result of the reproductive rate, mutation, heredity, and 
natural selection [1]. The evolutionary theory clearly predicts that intrinsic decline in 
function caused by the accumulation of damage, particularly at the molecular level 
and and eventually gives rise to age-related frailty and disease. At the molecular 
level, evidence suggests that several of the most important mechanisms involve 
damage to macromolecules. An increase in DNA damage is associated with ageing, 
which implicates the importance of DNA repair mechanisma at the rate of ageing 
processes [2]. When species with different longevity are compared, it has been seen 
that there is a linear relationship between longevity and DNA repair [3]. The loss of 
telomeric DNA is also seen in many human somatic tissues with ageing, and as a 
result there is a decline in cellular division capacity with ageing [4]. For example 
humans have higher capacity for DNA repair, stress resistance and shown to live 
longer than any other mammal [5].  
 2
It is suggested that there is a connection between molecular stress and ageing and is 
explained by the accumulation of mitochondrial DNA (mtDNA) mutations with age 
[6]. Heat shock proteins (HSPs) have previously been shown to be important in 
longevity because they help to sequester and if possible restore denatured proteins. 
When a decline occurs in their function, damaged proteins are increased in cells and 
many diseases including Cataract, Alzheimer’s disease and Parkinson’s disease may 
develop [7]. Ageing is a non-adaptive process and, therefore, is not programmed. 
The genes have not evolved to cause damage to accumulate, and the evolution of 
ageing can therefore be understood only as a side-effect of other causes of 
evolutionary change [8]. 
Ageing is widespread amongst animal species and the rate of aging is species 
dependent. In Figure1.1, the total life span and rate of senescence in different 
organisms is seen [9]. There are different factors that affect ageing in different 
spieces. Mutations in genes encoding constituents of the insulin/insulin-like growth 
factor (IGF)-like signalling (IIS) pathway can extend lifespan of the nematode 
Caenorhabditis elegans, the fruit fly Drosophila melanogaster and the mouse Mus 
musculus [10]. Dietary restriction is seen to reduce the date rate of Drosophila [11]. 
Some organisms, like the freshwater Hydra, show no signs of ageing at all [12]. 
Others like the Pacific salmon age all at once, just as soon as their once-in-a-lifetime 
chance of reproduction has come and gone. In the case of the Pacific salmon, the 
rapid postreproductive death of the adult appears to be driven by sex hormones. If a 
salmon has its gonads removed, it cannot of course reproduce, but it lives much 
longer [13]. Numerous single gene mutations, as well as some pharmacologic 
interventions, have been identified that extend the life span of C. elegans [14]. 
Ageing in the yeast Saccharomyces cerevisiae this is defined by the replicative life 
span, which is measured by the number of times an individual cell divides, and the 
lifespan in yeast is controlled by the coordination of metabolic activity and resistance 
to stress. Some 19 genes have been shown to play a role in determining yeast 
longevity most of which possess human homologues. These genes encode a wide 
variety of biochemical functions [15]. 
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Figure 1.1 Comparison of life spans and rate of senescence in spieces ranging yeast 
to bristlecone pine [9]. 
Successful aging is being free from disability (absence of diseases like heart disease, 
diabetes, chronic inflamatory diseases), having good physical and cognitive 
functioning and participating in social and productive activities [16]. Centenarians 
are the best example of successful aging. Centenarians do not have major age-
associated diseases, and are in good mental and physical condition [17]. Studies on 
centenarians show that genetic factors play an important role in longevity. It has been 
shown that centenarian offspring has less cardiovascular disease (CVD) and 
ischaemic heart disease when compared with general age-matched controls [18, 19]. 
It also has been demonstrated that cancer is delayed in families of centenarians [20].   
1.2.  Genetics of Ageing 
There is a lot of evidence that show genes affect ageing. For example, mutations on 
several genes affect the length of life in some organisms [21]. For instance, it has 
been seen that a mutation in the gene encoding Prophet-of-Pit-1 (PROP), a pituitary 
transcription factor that regulates the secretion of growth hormone and insulin 
production increases the length of life in a Mouse strain [22]. Nine classes of genes 
that affect aging is identified in C. elegans [23]. Specific mutations in daf-2, daf-16, 
daf-23, age-1 and clk-1 genes of C. elegans increase the nematode’s life-span three-
tofive-fold [24]. In yeast, sir–2, a nicotinamide adenine dinucleotide (NAD) 
dependent histone deacetylase, has been found to slow down aging [25]. Over-
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expression of Cu/Zn super oxide dismutase can increase the maximum life-span of 
transgenic Drosophila up to 48% [26]. It has been recently identified that a mutation 
in the mouse SHC gene (p66shc)  is associated with a 30% longer life-span [27]. In a 
study that used microarray technology identified groups of genes whose activities, 
when upregulated by the insulin/IGF-I pathway, promote either ageing or longevity 
in nematode worms [28]. It has been shown that an increase in P53 activity as a 
result of a deletion of a portion of one copy of the P53 gene is associated with cancer 
prevention but also accelerated aging in mice [29]. 
Studies in humans also show that genes play both role in ageing and longevity. In a 
study done in 310 centenarians and as controls 164 adults aged 20–70, a 
polymorphism (DD genotype) in Angiotensin-converting enzyme (ACE) gene has 
been found significantly more frequent in centenarians than in the controls indicating 
the beneficial effect of the genotype in maintaining human survival [30]. In another 
study,  the case-only approach is applied to detect the interaction effect on longevity 
between the renin (REN) gene and the mitochondrial haplotypes in 157 Italian 
centenarians. It has been reported that a highly significant interaction between REN 
allele 10 ( one of the five polymorphic alleles of REN defined by the number of short 
tandem repeats) and mitochondrial haplotype H is related to longevity  [31]. In an 
another study, V/V (I405V) genotype of cholesteryl ester transfer protein (CETP) 
gene is found to be associated with human longevity [32].  
There are also genetic diseases that show premature aging in their pathology such as, 
Werner’s syndrome (WS), which is a rare autosomal recessive disorder characterized 
by premature aging. It is caused by mutation of WS gene that causes genomic 
instability Individuals with this syndrome typically develop normally until they reach 
puberty. Following puberty they age rapidly, so that by age 40 they often appear 
several decades older. People affected by Werner syndrome usually do not live past 
their late forties or early fifties, often dying from the results of cancer or heart 
disease [33]. The other disorder about premature aging, Hutchinson–Gilford, is 
caused by mutations in lamin A. The people diagnosed with this disease usually have 
small, fragile bodies like those of elderly people. Later the condition causes wrinkled 
skin, atherosclerosis and cardiovascular problems [34]. 
Classical genetic studies attempt to identify the relative contribution of genetic and 
environmental components to the observed phenotype, such as family and twin 
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studies. These studies are important to understand the heritability (the ratio of the 
total genetic variance to the total phenotypic variance)  patterns of a given trait. 
In a family study that is done in four succesfully aged families show that there are 
many siblings achieving exceptional longevity in them. Average life span in these 
families ranging from 96-106 years old. In these families 50% of children reach 
extreme old age  [35].  
Twin studies, that compare the frequencies of desired traits in identical 
(monozygotic) twins to fraternal or nonidentical (dizygotic) twins, are performed in 
order to estimate the relative contributions of genes and environment. The studies 
that have been done in the Scandinavian twins show the heritability of life 
expectancy to be 20–30% [36].        
A study which has been done in cohorts of Danish, Finnish and Swedish twins born 
between 1870 and 1910 comprising 20,502 individuals followed until 2003–2004 
shows interesting results. Mean lifespan for monozygotic (MZ) twins increases 0.39 
[95% CI (0.28, 0.50)] years for every year his co-twin survives past age 60 years. 
This rate is significantly greater than the rate of 0.21 (0.11, 0.30) for dizygotic (DZ) 
ones. In addition to this, It has been found that having a co-twin surviving to old ages 
substantially and significantly increases the chance of reaching the same old age and 
this chance is higher for MZ than for DZ twins. The relative recurrence risk of 
reaching age 92 is 4.8 (2.2, 7.5) for MZ males, which is significantly greater than the 
1.8 (0.10, 3.4) for DZ males [37]. These studies implicate the importance of genetic 
factors but also the envrionment appears to have a substantial role in longevity. 
1.3. Influence of Cardiovascular disease (CVD) and Inflammation on Ageing 
The frequency of coronary disease, hypertension, heart failure and stroke increase 
exponentially with advancing age. While epidemiologic studies have discovered that 
aspects of lifestyle and genetics are risk factors for these diseases, age, per se, 
confers the major risk. Thus, being free from cardiovascular disease at advanced age 
increase the probability of longevity [38]. 
Cardiovascular disease (CVD) is the most common reason of illness and death in the 
world, both in developed and developing countries [39]. It refers to the class of 
diseases that involve the heart and/or blood vessels(arteries and veins) [40]. 
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Many risk factors, such as Hypercholesterolemia, age, sex, hypertension, diabetes, 
smoking, oxidized-low-density lipoproteins (LDL), small and dense LDL, 
homocysteine and inflammatory cytokines increase the frequency of atherosclerosis 
which is associated with the hardening and loss of elasticity of artery walls [41, 42, 
43, 44].  
Abnormal levels of lipoproteins are linked to atherosclerosis, increasing of low-
density lipoprotein (LDL) and decreasing of high-density lipoprotein (HDL) 
cholesterol levels promote risk of atherosclerosis [45].  
CVD is a multifactorial disease, so genetic factors and environmental conditions are 
both important in for developing cardiovascular disease [46].  
Many genes such as apolipoprotein E (APOE), angiotensin I converting enzyme 1 
(ACE), plasma cholesteryl ester transfer protein (CETP), paraoxonase 1 (PON 1)  
have been associated with CVD. They are also related to successful ageing [16]. 
Inflammation play a central role in the pathophysiology of atherosclerosis. 
Inflammatory cells such as monocytes/macrophages and T cells are found in the 
atherosclerotic lesions. Inflammatory cytokines such as Interferon-γ, Tumor Necrosis 
Factor-α (TNF-α), Interleukin (IL)-1 and IL–6 takes role in the development of 
atherosclerosis [47, 48]. IL–6 leads to plaque growth by stimulating endothelial 
activation, vascular smooth muscle cell proliferation and leukocyte recruitment. It is 
also important for the production of triglycerides which could influence the 
apperance of CVD. TNF-α increases vascular permeability during devolopment of 
atherosclerosis by stimulating expression of adhesion molecules and major 
histocompatibility complex (MHC) proteins. TNF-α is involved in obesity-related 
insulin resistance and prothrombotic effects. IL–10 has anti-atherogenic effects like 
causing inhibition of adhesion of LDL-activated monocytes to endothelium and 
down-regulation of fibrinogen biosynthesis [49]. 
Alzheimer’s disease, Parkinson’s disease, cancer, amyotrophic lateral sclerosis, 
atherosclerosis, myocardial infarction, rheumatoid arthritis and type 2 diabetes are 
controlled by chronic inflammatory mechanisms and they are all majorly age-
associated diseases [50].  
According to that there is a reduction in response to environmental stimuli with age. 
Mortality rate increases (92-fold for heart disease, 43-fold for cancer, greater than 
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100-fold for stroke, greater than 100-fold for chronic lung disease and 89-fold for 
pneumonia and influenza) in old people due to reduced capacity of immune system 
[51]. Therefore, inflammation which is an evolutionarily conserved stress response, 
is very important for the length or quality of life in older adults. It has been shown 
that cardiovascular morbidity and mortality rates are about double in chronic 
obstructive pulmonary disease (COPD) cohorts compared to the general population 
[52]. A typical autoimmune disease, systemic lupus erythematosus (SLE) is 
associated with an up to 50 times increased risk of CVD [53]. Experiments which has 
been done on animals show that immune reactions can modulate atherosclerosis 
development [47].  
1.4. Genetic Studies on Human Longevity and Candidate Genes 
Genes that are involved in immune response/infammation, response to stressors 
including oxidative stress, insulin/IGF1 signalling pathway have all been associated 
with increased longevity in the literature. There have been identified polymorphisms 
in those candidate genes and their frequencies were found to be significantly 
different in centenarians when compared to younger controls [54]. For instance, IL6 
gene and Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) gene have been 
associated with longevity in males [55, 56]. Also another gene for C-reactive protein 
(CRP) is found to be involved in the regulation of human longevity [57]. 
Another one is Toll like receptor TLR4 gene and its +896G+ polymorphism has been 
shown to be significantly associated with lower frequency of Acut Myocardial 
Infarction [58]. 
A recent study on cententerians has shown that the absence of M694V mutation on 
MEFV gene, which has role in inflammation, could be related to live longer and 
healthy [59]. Another study point out that the polymorphisms of insulin like-growth 
factor 1 receptor and phosphoinositide 3-kinase genes could be related to long 
life [60]. 
There are many more molecular genetic studies of successful aging and many genes 
have been associated with longevity. Angiotensin I converting enzyme 1 (ACE), 
plasma cholesteryl ester transfer protein (CETP), cytochrome P4501A1 (CYP1A1), 
klotho (KL), microsomal triglyceride transfer protein (MTP), paraoxonase 1 (PON1), 
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apolipoproteins A-I (APOA1), A-IV (APOA4), C-III (APOC3), and E (APOE), 
interleukins 1α(IL1A), 1β (IL1B), 2 (IL2), 6 (IL6), 8 (IL8), 10 (IL10), and 
12 (IL12), human leukocyte antigens A (HLA-A), B (HLA-B) and 
DRB1 (HLA-DRB1), transforming growth factor β1 (TGFB), tumor necrosis factor 
A (TNFA), sirtuin 3 (SIRT3) genes have been associated with longevity in previous 
studies [16]. 
In our study of successfully aged population free from chronic disease we have 
chosen to analyse four candidate genes, namely APOE, LDLR, APOJ and SIRT3. 
These are explained in more deatil in sections below. 
1.4.1. Apolipoprotein E (ApoE) and Diseases 
Apolipoprotein E (apoE) is a 299-amino acid glycoprotein which has role in binding 
of lipoprotein particles to the low density lipoprotein (LDL) receptor and the apoE 
receptor, so it has an important role in lipid metabolism [61, 62].  
The association of apolipoprotein E (apoE) gene polymorphism with many diseases 
such as coronary artery disease [63], Alzheimer's disease [64], coronary heart 
disease [65] has been shown in previous studies.  
Three common alleles, called ε2, ε3, and ε4, encode three major apo E isoforms; ε2, 
ε3 and ε4. There are six alternatives:  three homozygous phenotypes, ε2/2, ε3/3, ε4/4, 
and three heterozygous phenotypes, ε3/2, ε4/3, and ε4/2 [66]. These genotypes are 
caused by substitutions in amino acids at residue 112 and residue 158. The ε3 
isoform has cysteine and arginine at position 112 and 158, respectively. The ε4 has 
arginine and the ε2 has cysteine at both sites [67]. 
It has been shown that individuals who have ε4 alleles have decreased levels of high 
density lipoprotein (HDL) and increased level of low density lipoprotein (LDL) 
which increases the risk of coronary heart disease, and diminishes longevity [68]. In 
contrast, ε2 allele is related to lower LDL and total cholesterol [69]. In another study, 
ε4 has been found to be associated with higher serum total cholesterol and LDL 
cholesterol levels while ε2 is related to lower serum total cholesterol and LDL 
cholesterol levels in Turkish population [70]. 
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ε4 allele has been also associated with increased risk for Alzheimer's disease [71].  
ε2 allele has a positive effect on longevity. Frequency of ε2 is high in healthy 
individuals. On the other hand, ε4 allele has a negative effect on longevity. 
Frequency of ε4 is low in healthy individuals [72]. 
We hypothesized that there should be a decreased frequency of the E4 (ε4) allele and 
an increased frequency of the E2 allele (ε2) in our elderly population without chronic 
inflammation including heart disease. 
1.4.2. Low Density Lipoprotein Receptor (LDLR) and Diseases 
The low density lipoprotein receptor (LDLR) is a cell surface receptor that plays an 
important role in cholesterol homeostasis by removing low density lipoprotein (LDL) 
particles from the plasma via receptor-mediated endocytosis [73].  
LDLR is located on chromosome 19 at 19p13.1-p13.3 [74], over 1000 mutations 
have been identified in this gene [75]. 
LDLR receptor controls plasma cholesterol levels by the way of interacting between 
the LDL [76].  If there is a problem, low density lipoprotein (LDL) cholesterol levels 
increase and this is big risk factor for coronary heart disease (CHD) and 
cardiovascular disease (CVD) [77]. 
Mutations at the LDLR gene cause dysfunction of the receptor and lead to familial 
hypercholesterolemia [78]. Familial hypercholesterolemia (FH) is an autosomal 
dominant disease with increased total cholesterol and low density lipoprotein (LDL) 
cholesterol affecting one in 400–500 people in the general population [79, 80]. More 
than 600 different, but rare, mutations in the LDLR have been associated with 
familial hypercholesterolaemia, and AvaII RFLP (restriction fragment length 
polymorphism) is widely studied polymorphism of LDLR gene which has been 
found to be associated with familial hypercholesterolemia [81, 82]. AvaII RFLP is 
present in exon 13 and C to T change at 1959 bp creates the site for AvaII [83]. 
In our Project, we have looked the LDLR C to T change at 1959 bp in exon 13 in our 
elderly group who are free from chronic inflamatory diseases. We expect to see 
frequency of protective C variant more common than the other T allele. 
 
 10
1.4.3. Apolipoprotein J/ Clusterin (CLU) and Diseases 
Apolipoprotein J/ Clusterin (CLU) (otherwise called apolipoprotein J, sulfated 
glycoprotein–2, or testosterone-repressed prostate message- 2 among others) is a 
secreted glycoprotein and highly conserved. It is formed by two 40 kD sub which 
hold together by disulphide bonds [84].  
Many cells including epithelial and neuronal cells secrete clusterin constitutively and 
it circulates in all cell body fluids like serum, plasma and urine [85].   
ApoJ/clusterin functions include lipid transport, sperm maturation, complement 
defense, regulation of apoptosis, tissue remodeling, membrane protection, and 
promotion of cell-cell or cell–substratum interactions [86]. Moreover, CLU has been 
shown to function as an extracellular chaperone that stabilizes stressed proteins in a 
folding-competent state [87]. 
In human plasma ApoJ forms a high density lipoprotein (HDL) complex with 
apolipoprotein A-1 (apoA1) ,  cholesteryl ester transfer protein (CETP) and 
paraoxonase, so CLU may have function in the regulation of lipid transport [88]. 
Clusterin is upregulated in injured organs in many severe physiological disturbances 
states including Alzheimer’s disease, atherosclerosis, myocardial infarction, and 
kidney degenerative diseases [89, 90]. It is also induced in prostate and seminal 
vesicle carcinogenesis, ovarian cancer, pancreatic cancer, breast carcinoma [91, 92, 
93]. In addition, CLU serum levels increase significantly in diabetes type II and 
during development of coronary heart disease or at myocardial infarction [94]. 
It has been shown that apoJ/clusterin-deficient mice exhibit enhanced inflammatory 
severity and sequelae in an autoimmune myocarditis model, so it may serve an anti-
inflammatory role under some conditions [95]. 
Clusterin has been cloned as a senescence-induced gene and its upregulation during 
both replicative senescence and stress-induced premature senescence has been shown 
in human cells [96]. Clusterin expression is reduced in lymphocytes of healthy 
centenarians [97]. 
Because of these properties clusterin could be a biomarker of human aging and 
senescence. To investigate that we determined serum clusterin levels in our healthy 
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eldery group (n = 115) and in a control young group (n= 38) without a major 
disorder. 
1.4.4.  Sirtuin 3 (SIRT3) and Diseases 
The Sirtuin 3 (SIRT3) gene lies at the telomeric terminal on 11p15.5 chromosome 
(www.ncbi.nlm.nih.gov/omim: MIM 604481; contig NT_035113). It is a human 
homologue of the SIR2 genes [98]. Proteins involved in SIR2 gene familiy 
(nicotinamide dinucleotide phosphate (NAD+) -dependent protein deacetylases)   are 
implicated in chromatin structure, transcriptional silencing, metabolism and aging in 
organisms ranging from yeast to humans [99]. The proteins in this family also has 
been associated with inhibition of cardiac hypertrophy and enhanced cardiacmyocyte 
survival [100].  
SIRT3 has been shown that regulates the acetylation level and activity of acetyl-
coenzyme A synthetase 2, which could has a role in energy production in mammals 
under starvation conditions [101]. SIRT3 is reduced in muscle of diabetic animals 
[102], induced in white and brown adipose tissue in response to calori restriction and 
its overexpression affects expression of genes involved in mitochondrial function 
[103].  
A variable number of tandem repeats (VNTR) polymorphism of a 72-bp repeat core 
in intron 5 of the SIRT3 gene and presence of either a GATA3 or a delta-EF1 
regulatory site has been associated with longevity in males [104].  
In our Project, we also look VNTR polymorphism in intron 5 of the SIRT3 gene to 
search its association with longevity in our study population. 
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1.5.  Aim of The Study 
In this project, we have searched the association for APOE, LDLR, SIRT3 and APOJ 
genes’ polymorphisms in our elderly population free from chronic inflammatory 
disease including CVD. We hypothesized that there should be more protective alleles 
of these genes in our elderly population compared to historic controls, so they could 
come to old age without CVD or any major heart disease related inflammatory 
syndromes. 
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2. MATERIALS AND METHODS 
2.1. Materials and Laboratory Protocols 
2.1.1. Used Equipments 
The laboratory equipment used during this project is listed in Appendix A. 
2.1.2. Used Chemicals, Enzymes, Markers and Buffers 
The chemicals, enzymes and markers used are given in Appendix B together with 
their suppliers. The compositions and preparation of buffers and solutions are given 
in Appendix C. 
2.1.3. Used Kits 
The kits used and their suppliers are given in Appendix D. 
2.2. Selection Criteria of the Elderly group without chronic inflammation  
An elderly group free of chronic inflammatory disease was chosen among the 
patients from the outpatient clinics of the division of of Geriatrics of the Cerrahpasa 
Medical Faculty (CMF). A rheumatologist and a geriatrician selected an elderly 
group free of chronic inflammatory disease  among the outpatients of the geriatric 
division medicine.  The patients were over 60, did not have a history of any chronic 
inflammatory disease among those who attended clinic for routine health control 
examinations or follow up visits for hypertension, osteoporosis, osteoarthritis,  
hyperlipidemia or hypercholesterolemia (N=170). Sample selection has started two 
years ago and until now 170 elderly has registered into our database. CMF ethics 
committee approved the study protocol and oral informed consent was obtained from 
all participants.  
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2.3 Collection and Storage of Blood Samples 
The peripheral blood samples were collected from the patients in vacuum tubes 
containing EDTA. The samples were kept at −20 oC for short term storage (1-2 
weeks), and in −80 oC for longer terms of storage. 
2.4 DNA Isolation from Human Whole Blood 
The DNA isolation was done by Magtration System 8Lx Instrument, with the kit 
provided by the supplier (Precision System Science). Approximately 4 mL of blood 
sample was used for each isolation. The isolated DNA was kept at -20 °C after the 
working solutions were done (50 ng/μL) and the DNA samples were kept at + 4 °C. 
2.5 DNA Amount, Purity and Working Solution Calculations 
The concentration and purity of the isolated DNA is calculated by using the 
absorbance values measured at 260, 280 and 320 nm. The concentration of the DNA 
is calculated with the equation 2.1 and the purity of the DNA samples are calculated 
with the equation 2.2 given below: 
 
                       
(2.1) 
 
 
(2.2) 
 
2.6 Sample Collection For Clusterin Analysis 
Serum was isolated conventionally from the blood samples. Biovendor human 
clusterin ELISA kit was used to measure serum clusterin levels. ELISA analysis was 
done in Centre Biochemistry lab of Cerrahpasa Medical Faculty. Initially, an 
approximately equal numbers of female (N=46) and males (N=40) were chosen from 
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the database based on their entry into the database. After finding variation in serum 
the clusterin levels and positive correlation with hsCRP levels, a second set of people 
were chosen based on the top %5 high clusterin and high hsCRP (N=6) with the 
lowest %5 low clusterin and low hsCRP levels (N=6). These individuals were further 
studied for Denaturating Gradient Gel Electrophesis (DGGE) in order to find 
polymorphisms and/or mutations with in the APOJ gene. Finally, a group of young 
people (N=38) without known diseases were chosen from the students in Molecular 
Biology and Genetics department of Istanbul Technical University in Turkey. Their 
serum clusterin levels were compared with elderly population.  
2.7 The Principle of Human Clusterin ELISA Test 
The test kit is a solid phase enzyme immunometric assay (ELISA) in microplate 
format, designed for the quantitative measurement of human Clusterin in serum, 
plasma and CSF. This ELISA utilises two anti-human Clusterin Mouse monoclonal 
antibody and human serum based calibrator. 
Calibrators, quality controls and diluted samples are incubated in microtitration wells 
coated with first anti-human Clusterin monoclonal antibody. After a thorough wash, 
biotin-labelled second anti-human Clusterin monoclonal antibody is added to the 
wells and incubated with the immobilized antibody-Clusterin complex. After one-
hour incubation and a next washing step, streptavidin-horseradish peroxidase (HRP) 
conjugate is added and incubated for half an hour. After last washing step, the 
conjugate bound is allowed to react with the substrate (H2O2- tetramethylbenzidine - 
TMB). The reaction is stopped by addition of acidic solution, and absorbance of the 
resulting yellow product is measured spectrophotometrically at 450 nm. The 
absorbance is proportional to the concentration of Clusterin. A calibration curve is 
constructed by plotting absorbance values versus Clusterin concentrations of 
calibrators, and concentrations of unknown samples are determined using this 
calibration curve.  
2.8 C-reactive protein (CRP) 
C-reactive protein (CRP) is a plasma protein, an acute phase protein produced by the 
liver [105]. CRP is an inflammatory marker may be present in increased levels in the 
blood in patients at risk for cardiovascular disease [105]. hsCRP (high sensitivity-C 
 16
reactive Protein) assays are used to measure blood CRP levels [105]. hsCRP is 
measured by immunonephorometry which is an application of nephelometry to the 
quantification of antigen or antibody. The technique depends on the light-scattering 
properties of microparticles [106]. 
2.9 Rheumatoid Factor (RF) 
Rheumatoid Factors (RF) are auto antibodies that are usually produced in particular 
inflammatory diseases, mainly in Rheumatoid Arthritis (RA). On the other hand, RF 
production in the normal elderly people, in immunized normal people and in 
individuals with chronic inflammation or autoimmune conditions is also reported 
[107, 108]. RF is also measured by immunonephorometric techniques. 
2.10. Polymerase Chain Reaction (PCR) 
PCR was used to amplify the target DNA sequences on LDLR, SIRT3, APOE and 
APOJ genes which contained the related SNP regions [109, 104, 110, 111]. A 
standard mixture of PCR (except from the primers) was used to amplify the regions 
containing the related SNPs of our candidate genes. 
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Table 2.1 Standard PCR mixture 
Ingredient Stock Concentration Volume 
Final 
Concentration 
Taq Buffer 10X 2 μL 1X 
MgCl2 25 mM 1.5 μL 1.5 mM 
Forward Primer 10 pmol/μL 1 μL 0.5 μM 
Reverse Primer 10 pmol/μL 1 μL 0.5 μM 
dNTP mix 2 mM 0.4 μL 40 μM 
Taq Polymerase 5 U/μL 0.2 μL 0.05 U/μL 
dH2O − 7.9 μL − 
Template DNA 50 ng/μL 2 μL 100 ng 
Q Solution 5X 4 μL 1X 
FINAL 20 μL  
 
2.10.1. Oligonucleotide Primers 
The oligonucleotide primers used in this study were selected from previous studies 
[109, 104, 110] and are given in the table 2.2 below. They are confirmed on Amplify 
3X software [112] that they actually bind to the related sequence on APOE, SIRT3 
and LDLR genes. The efficiency of binding and the amplicon sizes are also 
determined with this software. 
It is also important to analyze the primer sets for dimer formation. The hairpin, 
heterodimer and self dimer analysis of the primer sets are done and confirmed with 
the SciTools on the IDT DNA website [113]. 
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Table 2.2 Oligonucleotide primers 
SNP Primer Sequence Amplicon 
Size 
Reference 
LDLR F-5’-GTCATCTTCCTTGCTGCCTGTTTAG-3’  
     228 bp 
 
[109] 
LDLR R-5’-GTTTCCACAAGGAGGTTTCAAGGTT-3 
APOE E2mut (5’ ACT GAC CCC GGT GGC GGA GGA GAC 
GCG TGC) 
318 bp [110] 
APOE E3 (5’ TGT TCC ACC AGG GGC CCC AGG CGC 
TCG CGG) 
SIRT3 F-5’-TTCCTGAAGCTGGGTACA-3’ 
399-759 [104] 
SIRT3 R-5’-CATTCACCTTCCCAAAGTGG-3’ 
 
2.10.2. PCR Optimization 
The PCR reactions usually need to be optimized for higher efficiency, amplification 
of the correct target and determination of appropriate annealing temperature for 
different primer sets. In this thesis, Mg2+ titration, Touchdown PCR and Gradient 
PCR methods were applied to optimize the PCR conditions. For PCR reaction of 
APOE gene, we additionally use DMSO and GC melt in order to dissolve GC rich 
regions of it. We also use Q solution for PCR reaction of APOE, SIRT3 and APOJ 
gene to prepare a better buffer condition for taq polymerase enzyme.   
2.10.3. Magnesium (Mg2+) Titration 
Mg2+ is the cofactor of Taq DNA polymerase, as well as many DNA polymerases. 
The amplification efficiency changes within a scale of low to high concentrations of 
Mg2+. Frequent observations about the effect of Mg2+ concentration on PCR includes 
the decrease in amplicon amount with low concentrations, and unspecific 
amplification of non-target regions with high concentrations. In order to obtain the 
appropriate amount of Mg2+ for a PCR reaction, Mg2+ titration should be applied. 
This procedure is usually done by setting up PCR mixtures that only differ in Mg2+ 
concentration. A used procedure for determination of Mg2+ concentration of PCR is 
given in table 2.3 below. 
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Table 2.3 Magnesium titration  
Ingredient 1.5 mM 2.0 mM 2.5 mM 3.0 mM 3.5 mM 
MgCl2 (25 mM) 1.2 μL 1.8 μL 2.4 μL 3.0 μL 3.6 μL 
ddH2O 12.2 μL 11.6 μL 11.3 μL 11.0 μL 10.4 μL 
F. Primer 1 μL 1 μL 1 μL 1 μL 1 μL 
R. Primer 1 μL 1 μL 1 μL 1 μL 1 μL 
10X buffer 2 μL 2 μL 2 μL 2 μL 2 μL 
Taq 0.2 μL 0.2 μL 0.2 μL 0.2 μL 0.2 μL 
dNTP 0.4 μL 0.4 μL 0.4 μL 0.4 μL 0.4 μL 
Template 2 μL 2 μL 2 μL 2 μL 2 μL 
 
2.10.4. Gradient PCR 
When appropriate annealing temperature is not known for a primer set, gradient PCR 
might be used to determine the optimum annealing temperature for a PCR reaction. 
In gradient PCR, the thermo cycler is set in such a way that the wells in the thermo 
cycler block have a gradient of temperature from high to low for the annealing phase 
of the cycles. So, a set of identical PCRs can be run in the same block with different 
annealing temperatures. When the PCR products are viewed with agarose gel 
electrophoresis, the PCR mixture that has the nearest annealing temperature to the 
optimum temperature should give the best band intensity. In this thesis, the gradient 
PCR was used to optimize the annealing temperature of APOJ PCR which is 
amplified for DGGE analysis, a gradient from 50 to 55 was used and the best bands 
were observed in 55 °C, and this temperature is used as the annealing temperature of 
promoter region of APOJ PCR for the rest of the studies. 
2.10.5. PCR Cycle Conditions 
The PCR conditions were modified according to the desired amplicon.  
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2.11. PCR Conditions of LDLR 
The standart PCR mixture of LDLR PCR is shown in the table 2.4 below. 
Table 2.4 Standard PCR mixture for LDLR 
Ingredient Stock Concentration Volume 
Taq Buffer 10X 2 μL 
MgCl2 25 mM 1.2 μL 
Forward Primer 10 pmol/μL 1 μL 
Reverse Primer 10 pmol/μL 1 μL 
dNTP mix 2 mM 2 μL 
Taq Polymerase 5 U/μL 0.2 μL 
dH2O − 9.6 μL 
Template DNA 50 ng/μL 3 μL 
FINAL                          20 μL 
 
The cycle conditions of LDLR PCR are shown in the table 2.5 below. 
Table 2.5 PCR cycle conditions for LDLR 
Repeat 
Number Degree Time Phase 
1 94 °C 3 minutes Initial Denaturation 
35 
94 °C 30 seconds Denaturation 
60 °C 30 seconds Annealing 
72 °C 30 seconds Extension 
1 72 °C 5 minutes Final Extension 
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2.12. PCR Conditions of APOE 
The standart PCR mixture of APOE PCR is shown in the table 2.6 below. 
Table 2.6 Standard PCR mixture for APOE 
Ingredient Stock Concentration Volume 
Taq Buffer with 
MgCl2 
10X 2 μL 
DMSO 25 mM 0.25 μL 
Forward Primer 10 pmol/μL 1 μL 
Reverse Primer 10 pmol/μL 1 μL 
dNTP mix 2 mM 2 μL 
Taq Polymerase 5 U/μL 0.2 μL 
dH2O − 6.55 μL 
Template DNA 50 ng/μL 3 μL 
Q Solution 5X 4 μL 
FINAL                           20 μL 
 
The cycle conditions of APOE PCR are shown in the table 2.7 below. 
Table 2.7 PCR cycle conditions for APOE 
Repeat 
Number Degree Time Phase 
1 94 °C 3 minutes Initial Denaturation 
40 
94 °C 10 seconds Denaturation 
65 °C 30 seconds Annealing 
72 °C 30 seconds Extension 
1 72 °C 7 minutes Final Extension 
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2.13. PCR Conditions of SIRT3 
The standart PCR mixture of SIRT3 PCR is shown in the table 2.8 below. 
Table 2.8 Standard PCR mixture for SIRT3 
Ingredient Stock Concentration Volume 
Taq Buffer 10X 2 μL 
MgCl2 25 Mm 1.2 μL 
Forward Primer 10 pmol/Μl 1 μL 
Reverse Primer 10 pmol/μL 1 μL 
dNTP mix 2 Mm 2 μL 
Taq Polymerase 5 U/μL 0.2 μL 
dH2O − 5.6 μL 
Template DNA 50 ng/μL 3 μL 
Q Solution 5X 4 μL 
FINAL 20 μL 
 
The cycle conditions of SIRT3 PCR are shown in the table 2.9 below. 
Table 2.9 PCR cycle conditions for SIRT3 
Repeat 
Number Degree Time Phase 
1 94 °C 1 minutes Initial Denaturation 
35 
94 °C 1 minutes Denaturation 
59 °C 1 minutes Annealing 
72 °C 1 minutes Extension 
1 72 °C 5 minutes Final Extension 
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2.14. Agarose Gel Electrophoresis of PCR Products 
The right percentage of an agarose gel is important for observing the PCR bands. In 
this thesis, all of the PCR products’ amplicon sizes are in a range between 195 to 360 
bp, which can be seen on a 1% agarose gel. In order to observe the PCR products of 
the APOE and LDLR polymorphisms, 1% mini or midi gels were prepared. For 
SIRT3 1.5% mini or midi gels were prepared. Mini gels were prepared with 0.5 g or 
0.75 g agarose and 0.5 μg/mL ethidium bromide added into 50 mL of 1X TBE 
buffer, which was diluted from 10X stock TBE. Similarly, %1 and %1.5 midi gels 
were prepared with 1.5 g or 2.25 g agarose and 0.5 μg/mL ethidium bromide added 
into 150 mL of 1X TBE buffer.  5 μL of PCR product was mixed with 1 μL 6X 
loading dye and loaded into the wells. Gene ruler 1 kb (Fermentas) and Gene ruler 
low range (Fermentas) markers (can be seen in appendix B) were used as DNA 
ladder in order to calculate the lengths of the PCR products. The gels were run in 1X 
TBE buffer, at 120V with power supplier, for at least 30 minutes. The gels were 
observed under UV light with a transilluminator, and pictures were taken with UV 
PhotoMW software. 
2.15. Restriction Enzyme Digestion of PCR Products 
The restriction enzyme digestions of the PCR products were done according to the 
protocol provided by supplier of the enzymes. Restriction enzyme digestions were 
also performed and confirmed in electronic environment with EnzymeX 
software [114]. The general protocol is given in table 2.10 and the restriction 
enzymes and expected fragment sizes are given in table 2.11 below. 
Table 2.10 Restriction Enzyme Digestion mixture  
Ingredient 1X amount 
10X reaction buffer 2 μL  
ddH2O 7.5 μL  
Restriction Enzyme (10 U/μL) 0.5 Μl 
Amplicon 10 μL  
Final Volume 20 μL  
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The restriction enzyme mixture containing PCR products were kept at 37 °C 
overnight for digestion. Digestion and the RE are inactivated by application of the 
mixtures to 80 °C for 30 minutes. 
Table 2.11 Restriction Enzymes used for each polymorphism and expected fragment 
sizes 
SNP Restriction Enzyme Amplicon bp Expected Fragments 
APOE AflIII 318 ε4: 295 bp ε2 and ε3: 231/232 bp 
APOE HaeII 318 ε2: 267 bp ε3 and ε4: 231/232 bp 
LDLR AvaII 228 
Wild Type: 1 fragment (228 bp) 
Mutant: 2 fragments (141+ 87 bp) 
2.16 Agarose Gel Electrophoresis of Restriction Enzyme Digested PCR Products 
In this thesis, the RE digested bands are observed in agarose gels of concentrations 
between 2% to 4%, according to the size of the products and the minimum band size 
difference that can be discriminated. LDLR restriction enzyme digested products 
were viewed in 2%, APOE restriction enzyme digested products were viewed in 4% 
and SIRT3 PCR products were viewed in 1.5% mini or midi agarose gels. In all of 
the restriction analyses 10 μL of RE digested PCR product is mixed with 2 μL of 6X 
loading dye and loaded into the wells. The gels are run in 1X TBE buffer, at 120V, 
for at least 30 minutes. The gel pictures are taken with UV PhotoMW software. 
2.17. Genotyping 
The genotyping was done by analyzing the agarose gel photos of the RE digested 
PCR products for APOE and LDLR genes and PCR products for SIRT3. Gene (allele 
and genotype) frequencies were calculated by counting. Low range marker 
(Fermentas) was added to decide the band sizes along with positive controls. This 
was done separately and blindly by myself and by my advisor Dr. Eda Tahir Turanlı. 
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2.18. Denaturing Gradient Gel Electrophoresis (DGGE) 
Denaturing Gradient Gel Electrophoresis (DGGE)  is a sensitive technique for 
separation of different changes in DNA sequence. Single base pair substitutions, 
insertions and deletions can be detected by DGGE with high efficiency [115]. DNA 
molecules denaturate at different melting temperatures which is called Tm (melting 
temperature) when they subjected to an acrylamide gel which has a gradient with an 
increasing concentration of denaturant [116]. Urea and formamide are used to form a 
denaturing environment. The DNA molecules that contain one or more different 
nucleotides have different melting temperatures, and they could be separated 
efficiently on gel. Differences in the amount of denaturation between DNA strands 
cause different migration patterns along the gel. Each of them will be seen as a 
separate band after visualization of gel under UV via using ethidium bromide or 
SYBR-Gold [117].  
2.18.1. PCR For DGGE Analysis 
Primers were selected to cover all coding regions and several noncoding regions of 
the APOJ gene in order to find polymorphisms and/or mutations with in the APOJ 
gene. The list of primers for PCR reaction of CLU is given in table 2.12. We 
determine these primers via fast PCR program and previous studies [111]. 
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Table 2.12 APOJ gene primers 
PRİMER NAME AND SEQUENCE REGION PRODUCT SIZE 
TM 
(ºC) 
CLU-PROM1517F: GGACGGATGCATGACCTAAG PROMOTER 130 bp 55.4 
CLU-PROM1517R: CTTGTCCAAGCCACATCCTC   55.9 
CLU-PROM1141F:TAGAGGGGATGGGCAGTGT PROMOTER 157 bp 57.9 
CLU-PROM1141R: CGACTCACCCACAGACAAGA   56.6 
CLU-E1-F:  GCAGGCTGTCTAGCTGTTCCCA EXON1 260 bp 61.5 
CLU-E1-R: TCTGACCTCATCACCCTGTG   56.3 
CLU-E2-F:  TCTTCCTCTCGCCTCATTCT EXON2 275 bp 55.2 
CLU-E2-R: GCAGTGGGATGGTCAAGGCA   60.3 
CLU-E3-F:  GCCCAGCCTTGTGTCTTCCTGTA EXON3 270 bp 61.2 
CLU-E3-R: ACTCAGAGCCTTGGCCACT   58.9 
CLU-E4-F: GCCTCCTAACTGTGCCCATGCT EXON4 505 bp 61.9 
CLU-E4-R: ATGAGCTTCCACCCCTTCTC   56.7 
CLU-E5-F: GCATGGCTGGATGACTGAC EXON5 156 bp 56.2 
CLU-E5-R: CGACTCACCCACAGACAAGA   56.6 
CLU-E6-F: TCACTTGCGTTTCTTCCATC EXON6 395 bp 53.1 
CLU-E6-R: GCCTGCCGTGTGATAAATGCTC   58.9 
CLU-E7-F: GCATGCATTTTGACCACAGT EXON7 289 bp 54.3 
CLU-E7-R: GCAAAGGCCCGCCTGCTTAC   62.1 
CLU-3UTR1-F: TGTTTTACTTTGGAGGATAACTGTTT UTR1 230 bp 53.1 
CLU-3UTR1-R: GCTCGAGTGTTAGAGTGCAGGA   58.6 
CLU-3UTR2-F: GCACGTCACCAAGTAACCAGGC UTR2 240 bp 60.8 
CLU-3UTR2-R: CGGAAGCAGCAACTCAACA   55.9 
CLU-INTRON2182-F: GTGTCTGGGCCCACTCTG INTRON1 154 bp 58.2 
CLU-INTRON2182-R:CTGGGAGCTGGGCTAAGG   57.8 
CLU-INTRON2317-F: ACTTTCGGCTGTTGCATTTC INTRON2 157 bp 54.2 
CLU-INTRON2317-R: AAACCGTCAGCTCACAGGAG   57.2 
 
2.19 PCR Conditions of APOJ 
The cycle conditions of APOJ PCR are shown in the table 2.13 below. 
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Table 2.13 PCR cycle conditions for APOJ  
Repeat 
Number Degree Time Phase 
1 94 °C 5 minutes Initial Denaturation 
40 
94 °C 30 seconds Denaturation 
53-59 °C 45 seconds Annealing 
72 °C 45 seconds Extension 
1 72 °C 5 minutes Final Extension 
 
The standart PCR mixture of APOJ PCR is shown in the table 2.14 below. 
Table 2.14 Standard PCR mixture for APOJ 
Ingredient Stock Concentration Volume 
Taq Buffer with 
MgCl2 
10X 2 μL 
Forward Primer 10 pmol/Μl 1 μL 
Reverse Primer 10 pmol/μL 1 μL 
dNTP mix 2 Mm 2 μL 
Taq Polymerase 5 U/μL 0.2 μL 
dH2O − 6.8 μL 
Template DNA 50 ng/μL 3 μL 
Q Solution 5X 4 μL 
FINAL                         20 μL 
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Only annealing temperature is different for different regions of the APOJ PCR (see 
table 2.15). 
Table 2.15 Anneling temperatures of APOJ PCRs 
APOJ PCR Annealing temperature 
APOJ 1517, E1, E2, E5 and E6 55 °C 
APOJ 1141 and 2317 56 °C 
APOJ E3 53 °C 
APOJ E4, UTR2 and 2182 57 °C 
APOJ E7 59 °C 
 
2.18.2. DGGE Conditions  
For DGGE, the PCR products subjected to electrophoresis for 4 hours at 120 v, 60 
°C a 7–8% polyacrylamide gel containing a 30–70% denaturing gradient in TAE 
buffer. After electrophoresis gel is visualizised under ultraviolet illumination via 
using SYBR-Gold. 
2.18.3. Sequencing 
For sequence PCR, we use PCR products as template for sequence PCR. They 
subjected to cycle sequencing in both directions using the BigDye version 3.0 
sequencing kit. After that, they are purified and given to machine for direct 
sequencing. 
2.20. Statistical Analysis 
2.20.1. Association studies 
Studies concerning genetic association aim to test if there are differences between 
two groups (e.g. diseased subjects and healthy controls) in candidate genes or in 
whole genomes. Genetic association studies may take one of two approaches, either 
family-based, or population based. The former employ the family of tests known as 
Transmission Disequilibrum Tests (TDT) which detect association in the presence of 
linkage. Other studies do not focus on families where a praticular disease is 
segregating, instead samples of affected and unaffected individuals are drawn from 
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the population, and the frequency with which certain alleles are present in each of 
these groups is tested for association with a disease [118]. In this thesis we compared 
the elderly group gene frequencies with appropriate historic controls from the 
literature. 
2.20.2. Chi-square analysis 
Chi-square test ( χ2 test ) is any statistical hypothesis test in which the test statistic 
has a chi-square distribution when the null hypothesis is true, or any in which the 
probability distribution of the test statistic (assuming the null hypothesis is true) can 
be made to approximate a chi-square distribution as closely as desired by making the 
sample size large enough. It is a non-parametric analysis and the best-known 
situations in which the chi-square distribution are used are the common chi-square 
tests for goodness of fit of an observed distribution to a theoretical one, and of the 
independence of two criteria of classification of qualitative data [119]. 
2.20.3. Odds ratio 
It is defined as the ratio of the odds of an event occurring in one group to the odds of 
it occurring in another group, or to a sample-based estimate of that ratio. These 
groups might be men and women, an experimental group and a control group. Odds 
ratio calculations were done with the online tool from Simple Interactive Statistical 
Analysis (SISA) [120]. Odds ratio is generally used to compare the probability of a 
certain event in two groups. An odds ratio of 1 implies that the condition (or event) is 
equally possible in both of the case and the control groups [121]. 
2.20.4. Student t-test  
A t-test is any statistical hypothesis test in which the test statistic has a Student's t 
distribution if the null hypothesis is true. It is applied when sample sizes are small 
enough that using an assumption of normality. It is a parametric and quantitative 
analysis [122]. 
2.20.5. P-value 
P value (the level of significance) accounts for the probability of any difference 
observed between two data sets is only by chance. As a result, the lower the p value, 
the more evidence for rejecting the null hypothesis. In this thesis, the obtained data 
was designated into levels of significance according to the p value intervals: 
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If P>0.05, there is no significant difference 
If P<0.05, the difference is significant 
If P<0.01, the difference is highly significant 
If P<0.001, the difference is extremely significant 
All the tests were done using SPSS software (version 15.0).  
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3. RESULTS  
3.1. DNA Isolation Results 
In this thesis, Magtration System 8Lx DNA isolation procedure was followed for all 
the samples. The average DNA concentration obtained from Magtration System 8Lx 
instrument and kit is 261.2 ng/μL and average A260/A280 value is 1.8 (N=155).  
3.2. Demographic Data of the Elderly Group without Chronic Inflamatory 
Diseases  
The healthy elderly group in this study was made up of mostly women (75.1%) and 
had an average age of 74.125 (SD=6.553). Among the healthy individuals who were 
free from any chronic or acute illnesses we observed the presence of hypertension, 
osteoporosis, and osteoarthrosis (Table 3.1). Majority of the sample had normal 
levels of hsCRP and RF values. 
Table 3.1 Demographic properties of the Elderly Group 
Healthy Elderly         N=162 Percentage
 Gender             Female             Male 
75.1 
24.9 
Hypertension 73.9 Female 73.5% Male 75% 
Osteoporosis 52.8 Female 62.8% Male 22.5% 
Osteoarthrosis 29.1 Female 32.2% Male 20% 
Averages Female Male 
Average Age: 74.125  
(95% C.I=67.57-80.67, 
SD=6.553) 
73.608 75.675 
N=138 hsCRP < 5 IU/mL 91% 
RF < 15 mg/UL 
 
88% 
                                                              hsCRP < 5 IU/mL + RF < 15 mg/UL = 83 % 
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3.3. Association Analyses: Comparison of Elderly Candidate Genes With 
Historic Controls 
3.3.1. LDLR RESULTS  
Elderly group allele and genotype results for LDLR C1959T in exon 13 are given in 
table 3.2 below. 
Table 3.2 LDLR C1959T Allele Frequencies 
SNP Healthy elderly group ( N=168 ) 
LDLR 
C: 0.70 (117 of 168) 
                T: 0.30 (52 of 168) 
                CC: 77  (168) 
                CT: 81  (168) 
                TT: 10  (168) 
 
The elderly group genotype/allele data was compared with historic controls from the 
literature (see table 3.3). We hypothesize to see protective C allele frequencies more 
in the elderly group compared to historic controls. 
Table 3.3 LDLR C1959T Polymorphsim – comparison with historic controls 
SNP 
The healthy elderly 
group of genetic 
analysis 
( N=168 ) 
Bertolini et al, 1992
Italian population 
(General, Healthy)
( N= 183 ) 
[123] 
Chaves et al, 1991 
Spanish population 
(General, Healthy) 
( N= 61 ) 
[124] 
LDLR C: 0.70 T: 0.30 
C: 0.552 
T: 0.448 
C: 0.625 
T: 0.375 
 Not significant   
 
There were no significant differences between healthy elderly group with historic 
controls. We further subdivided the sample for, gender; presence of hypertension, 
osteoporosis, and osteoarthrosis and searched if there was any association between 
these factors with the polymorphism. 
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We found a significant difference (P=0.042) with presence of hypertension and the 
frequency of C1959T allele of LDLR gene. In other words, the risk T allele is more 
commonly and significantly present in people who have hypertension than the people 
without hypertension (see Table 3.4). 
Table 3.4 LDLR C1959T Polymorphsim - Hypertension 
 LDLR  CC CT/TT Total 
Hipertansiyon No 25 16 41 Yes 52 70 122 
Total 77 86 163 
X2=4.147 P=0.042   
 
3.3.2 APOE RESULTS 
Elderly group allele and genotype results for APOE are given in table 3.5 below. 
Table 3.5 APOE polymorphism results in our elderly group 
SNP The elderly group ( N=151) (percentage) 
APOE 
                   E2: %37 (113) 
                   E3: %50 (153) 
                   E4: %12 (36) 
                   E2/E2  %4.6 ( 7 ) 
                   E2/E3  %52.3 ( 78 ) 
                   E2/E4  %14.7 ( 22 )  
                   E3/E3  %18.7 ( 28 ) 
                   E3/E4  %9.3 ( 14 )  
                   E4/E4  0   ( 0 )                                 
 
We except to see ε2 alleles of APOE gene higher and ε4 alleles of APOE gene lower 
in our elderly group. When we compared our results with historic controls, we found 
that, the protective ε2 allele frequency is higher in our group as we assumed 
(x2=20.73, p<0.0001). However, there is not a significant difference between ε4 
allele frequencies. The observed allele frequencies are given in table 3.6 below. 
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Table 3.6 APOE Polymorphism analysis – comparison with historic controls 
SNP The elderly group      ( N=151) (percentage) 
Turkish Controls 
(94 healthy individuals ) 
[125] 
Longevity 
Galinsky 
Cambridge, UK 
( N=282 ) 
[126] 
APOE 
E2: 113 (%37) 
E3: 153 (%50) 
E4: 36 (%12) 
E2: 12 (%13.2) 
E3:  64 (%68.1) 
E4:  18 (%18.7) 
E2: 22 (%8) 
E3:  225(%80) 
E4:  33 (%12) 
 X2=20.73, p<0.0001   
 
3.3.3 SIRT3 RESULTS 
Elderly group allele and genotype results for SIRT3 VNTR polymorphism in intron 5 
of the gene are given in table 3.7 below. 
Table 3.7 SIRT3 polymorphism results in the elderly group 
The healthy elderly group of genetic analysis 
(N=166) 
SIRT3 
 Allele frequencies         Genotype frequencies 
        1:0.58,                1/1:95       2/2:24,    3/3:10 
         2:0.15,               1/2:2,        2/3:2,      3/4:14 
         3: 0.11,              1/3:0,        2/4:0,      3/5:1 
         4: 0.11,            1/4:1,      2/5:0,     4/4:9 
         5: 0.03,            1/5:0,      4/5:5,     5/5:3 
         6: 0 
 
As the increased repeat number is associated with longevity, we hypothesized that 
there should be more of the repeat in our group than historic controls. The observed 
allele frequencies are given in table 3.8 below. There was no significant difference 
on VNTR polymorphism in intron 5 of the SIRT3 gene between the elderly 
population and historic controls. 
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Table 3.8 SIRT3 Polymorphism analysis – comparison with historic controls 
The healthy elderly 
group of genetic 
analysis 
(N=166) 
Italians 20- to 80-year-old 
subjects 
( N= 703 ) 
[104] 
SIRT3 
1:0.58 
 
2:0.15 
3: 0.11 
4: 0.11 
5: 0.03 
6: 0 
Sum: 0.42 
1:  0.41 
 
2: 0.12 
3: 0.20 
4: 0,25 
5: 0.04 
6: 0.04 
Sum: 0.59 
 
3.3.4. RESULTS OF SERUM CLUSTERIN LEVEL 
Serum Clusterin levels were compared between different groups. A significant 
difference was found between elderly group and young controls (P= 0.01) (see table 
3.9). As we expected, we found serum clusterin levels lower in the elderly group than 
in the young group. 
Table 3.9 Serum clusterin levels- comparison with young controls 
 Groups N Minimum Maximum 
Mean 
(μg/mL) 
Std. 
Deviation 
Serum 
Clusterin 
Level 
(μg/mL) 
Elderly 115 41.67 440.40 186.3956 86.83414 
Young 38 128.01 333.30 210.9079 54.56490 
T=2.091 P= 0.01      
 
We also compared males and females within and between groups.  In the elderly 
group there was a significant difference among the females and males (higher in the 
females (p= 0.01) (Table 3.10). 
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Table 3.10 Serum Clusterin Levels-Gender in Elderly Group 
 Gender N Mean (μg/mL) 
Std. 
Deviation 
Std. Error 
Mean 
Serum 
Clusterin 
Level 
(μg/mL) 
Male 39 160.3646 62.69081 10.03856 
 Female 76 199.7536 94.53366 10.84375 
 T=5.97 p=0.01     
 
On the other hand, the same correlation was not seen among the young group 
(Table 3.11).  
Table 3.11 Serum Clusterin Levels-Gender in Young Group 
 Gender young N 
Mean 
(μg/mL) 
Std. 
Deviation 
Std. Error 
Mean 
Serum 
Clusterin 
Level 
(μg/mL) 
Male 18 222.0533 60.54144 14.26975 
Female 20 200.8770 47.90520 10.71193 
 Not significant     
 
As it was expected comparison of only males serum clusterin levels between and 
young and old groups revealed a highly significant difference (males having lower 
clusterin levels in the elderly) (P= 0.0005) (Table 3.12). 
Table 3.12 Serum clusterin levels- comparison with young controls in males 
 Groups N 
Mean 
(μg/mL) 
Std. Deviation 
Serum 
Clusterin 
Level 
(μg/mL) 
Elderly 39 160.3646 62.69081 
Young 18 222.0533 60.54144 
T=3.557 P= 0.0005    
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In contrast, we could not see a difference between these two groups when we 
compare only females (see table 3.13) 
Table 3.13 Serum clusterin levels- comparison with young controls in females 
 Groups N 
Mean 
(μg/mL) 
Std. Deviation 
Serum 
Clusterin 
Level 
(μg/mL) 
Elderly 76 199.7536 94.53366 
Young 20 200.8770 47.90520 
 Not Significant    
 
We also compared serum clusterin levels with hsCRP levels, which is an important 
inflammation marker.  We found a positive correlation (p= 0.001) between serum 
clusterin levels and hsCRP positivity. Serum level of clusterin is significantly higher 
in people whose hsCRP levels are above 3 IU/mL. Results of these analyses are 
given in table 3.14. 
Table 3.14 Serum Clusterin Levels- comparison with serum hsCRP levels 
 hsCRP N Mean (μg/mL) 
Std. 
Deviation 
Std. 
Error 
Mean 
Serum 
Clusterin 
Level 
(μg/mL) 
Under 3 IU/mL 70 157.3141 62.70578 7.4947 
 Above 3 IU/mL 44 233.8814 99.64733 15.0224 
 T=12.23, P=0.001     
3.4. DGGE RESULTS 
After finding positive correlation with increased clusterin levels with hsCRP we 
wanted to search for polymorphisms/mutations along the CLU gene using DGGE. 
First we analysed the promoter region and selected 6 people from each group (people 
having highest and lowest hsCRP+clusterin levels) and performed the analysis. Our 
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preliminary analysis revealed differences among the samples (Figure 3.1). However 
further analyses are needed to understand the type of variation, such as sequencing.  
 
Figure 3.1. Results of promoter region for APOJ 
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4. CONCLUSION & DISCUSSION 
Our research on the  elderly population free from chronic inflammatory diseases has 
initially started to search for MEFV gene mutations and compare their frequencies 
with historic controls. To this end we have collected samples from  elderly 
population over the two years (N=170) from Cerrahpasa Medical School. Our initial 
hypothesis was the less frequent occurance of MEFV mutations in the healthy elderly 
population was rejected. We did not see differences in their frequencies between 
elderly and Turkish historic controls [127]. We wanted further analyse the genetic 
properities of this population.  
Cardiovascular Diseases (CVD) account for about 50% of all deaths worldwide. 
CVD causes deaths almost twice of  cancer and 10 times of  accidents [128].16.7 
million deaths occur because of CVD per annum (WHO). Inflammation plays an 
important role in CVD. Many diseases such as chronic obstructive pulmonary 
disease (COPD) and systemic lupus erythematosus (SLE) that are related to 
inflammation, increase the risk of CVD [28, 29]. Thus, being free from inflammation 
may decrease the risk of CVD and increase the chance of survival at old ages. We 
have searched this hypothesis in an elderly population free of conditions associated 
with chronic inflammation.  
We therefore investigated the associations of APOE, APOJ, LDLR and SIRT3 genes 
in our elderly group. The association of these genes with CVD have been shown in 
previous studies. We expected to see the frequency of  protective alleles more 
common in the elderly group. A positive correlation between APOE ε2 allele and 
longevity is found from our study as we expected when we compare our elderly 
group with historic controls (x2=20.73, p<0.0001). The positive effect of ε2 allele on 
longevity has been show in previous studies [42]. However, we have detected a 
negative correlation between APOE ε4 allele and longevity. In previos studies, it has 
been seen that ε4 allele has a negative effect on longevity. Frequency of ε4 is low in 
healthy individuals [42]. In addition, a study by Heijmans et all in 2000, has shown 
the deleterious effect of ε4 homozygosity on mortality at old ages [2], and there is 
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not a person with ε4/ε4 phenotype in our group that confirm this data. It has been 
shown that mutations at the LDLR gene cause dysfunction of the receptor and lead to 
familial hypercholesterolemia [48]. We hypothesize to see the protective C1959 
allele LDLR higher in our elderly group. However, this study should be compared 
with a Turkish control group to have a more reliable data. In subgroup analysis, we 
found a significant difference (F= 4.417, P=0.042) with presence of hypertension and 
the frequency of LDLR C1959T polymorphism. In other words, the risk T1959 allele 
is more commonly and significantly present in people who have hypertension than 
the people without hypertension. It is reported that a variable number of tandem 
repeats (VNTR) polymorphism of a 72-bp repeat core in intron 5 of the SIRT3 gene 
and presence of either a GATA3 or a delta-EF1 regulatory site has been associated 
with longevity in males [74]. We have not seen a positive association between 
VNTR polymorphism in intron 5 of the SIRT3 gene and longevity. We will also look 
the presence of either a GATA3 or a delta-EF1 regulatory site by direct sequencing. 
High serum clusterin levels is associated with many diseases like Alzheimer’s 
disease, atherosclerosis, myocardial infarction, diabetes type II and coronary heart 
disease [59, 60, 64]. Therefore, we hypothesized to see lower serum clusterin levels 
in our elderly group than in our young group without any disorders. We have 
detected a significant difference between serum  clusterin levels when we compared 
our healthy elderly group with healthy young group (F=2.091, P=0.01). Serum 
clusterin levels was lower in elderly group as we expected. We found a significant 
difference (F= 5.97, P= 0.01) when we compared males and females in elderly 
group. Serum clusterin levels were higher in females than in males in the elderly 
group. We have seen a positive correlation between serum levels of clusterin and 
longevity in males (F= 3.557, P=0.0005). However, we have not seen this effect in 
females. As expected there was no significant difference in clusterin levels in the 
young group. Subgroup analysis in our elderly group has indicated that there is a 
positive correlation between serum clusterin levels and hsCRP positivity (F=12.23, 
P=0.001). This data confirms our suggestions. hsCRP positivity increases the risk of 
CVD, and higher serum clusterin levels is also associated with increased CVD risk. 
We have seen that people with hsCRP positivity have increased serum clusterin 
levels in our elderly group. Variations on clusterin levels will be further analysed at 
the DNA level.  
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In future, families of the individuals can be collected to do family based association 
studies or linkage analyses. We could also analyze the risk of CVD in siblings of 
elderly group to detect if protective alleles of our genes are higher between them. 
These studies can be better done using highthroughput analysis such as microarray 
techniques. We should also look serum clusterin levels in a more large group to test 
our significant results that we detected about male longevity. We could  also look 
effect of high serum clusterin levels on mortality at old ages.  
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APPENDIX A 
 
LABORATORY EQUIPMENT 
Balances    Precisa 620C SCS 
     Precisa BJ 610C 
Centrifuges    Sigma 1-13 B. Braun International 
     Allegra 25R Centrifuge Beckman Coulter 
Electrophoresis equipments E – C mini cell primo EC320 
Gel Documentation System  UVI PhotoMW Version 99.05 for Windows 
Pipettes    Gilson Pipetman 20 μL 200 μl, 1000 μl 
     Thermo Finnpipette 10 µL,  
pH meter     Mettler Toledo MP220 
Spectrophotometer   PerkinElmer Lambda25 UV/VIS Spectrometer 
Thermo cycler   Applied Biosystems GeneAmp PCR  
System 2700 
Corbett PalmCycler  
Techne FTGENE 5D 
Transilluminator   Biorad UV Transilluminator 2000 
Vortex    Herdolph Reax top 
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APPENDIX B 
 
CHEMICALS 
Agarose    AppliChem 
Boric acid    Amresco 
dNTP     Fermentas 
EDTA     AppliChem 
Ethanol    Riedel-de Haën 
EtBr     Amresco 
MgCl2     Fermentas 
Na2HPO4.7H2O   Riedel-de Haën  
NaH2PO4    Riedel-de Haën 
NaOH     Riedel-de Haën 
Primers    IDT DNA 
NaCl     Carlo Erba 
Tris Base    Amresco 
10X PCR Buffer   Fermentas 
                                                            Qiagen 
                                                            Roche 
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ENZYMES 
AflIII     Roche 
AvaII     Fermantas 
HaeII     Roche 
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MARKERS 
Gene RulerTM 1 kb DNA Ladder    Fermentas 
 
 
Gene RulerTM DNA Ladder Low Range  Fermentas 
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APPENDIX C 
BUFFERS 
TE Buffer  
Tris base     10 mM 
EDTA     1 mM 
Add ddH2O to 1 liter and adjust the pH to 8.0 
TBE (Tris-Borate-EDTA) Buffer (10X) 
Tris base    108 g  
Boric Acid    55 g 
EDTA     40 ml (0.5 M, pH 8.0) 
Add ddH2O to 1 liter and adjust the pH to 8.0 
Mini Agarose Gel (1%)  
Agarose    0.5 g 
TBE buffer (1X)   50 mL 
Add 1.5 μL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
Midi Agarose Gel (1%)  
Agarose    1.5 g 
TBE buffer (1X)   150 mL 
Add 4.5 μL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
Mini Agarose Gel (2%)  
Agarose     1 g 
TBE buffer (1X)   50 mL 
Add 1.5μL EtBr (final concentration: 0.5 mM) before pouring the gel into tray.  
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Midi Agarose Gel (2%)  
Agarose     3 g 
TBE buffer (1X)   150 mL 
Add 4.5μL EtBr (final concentration: 0.5 mM) before pouring the gel into tray.  
Mini Agarose Gel (4%)  
Agarose     2 g 
TBE buffer (1X)   50 mL 
Add 1.5μL EtBr (final concentration: 0.5 mM) before pouring the gel into tray. 
Midi Agarose Gel (4%)  
Agarose    6 g 
TBE buffer (1X)   150 mL 
Add 4.5μL EtBr (final concentration: 0.5 mM) before pouring the gel into tray.  
APPENDIX D 
USED KITS 
DNA Isolation  8 Lx Magtration® Genomic DNA kit 
 
Human Serum Clusterin            Biovendor 
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